Back to discover
Disease

Sexual Dysfunctions, Psychological

Late-stage therapeutic developmentEmerging research
MeSHSexual Dysfunctions, Psychological
1
Publications
10
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional Platelet Rich Plasma for Peyronie's Disease
Results expected Q1 20272026-06-04
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
10
All trials
1
Active
6
Late-stage
6
Completed
Late-stage studies

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional Platelet Rich Plasma for Peyronie's Disease

Phase 4 · Active, not recruiting · University of Miami

24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States

Phase 3 · Completed · Sprout Pharmaceuticals, Inc

A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD

Phase 3 · Completed · Sprout Pharmaceuticals, Inc

A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder

Phase 3 · Completed · Sprout Pharmaceuticals, Inc

Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire

Phase 3 · Terminated · Sprout Pharmaceuticals, Inc

24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America

Phase 3 · Terminated · Sprout Pharmaceuticals, Inc
Recently completed

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Of Bupropion Hydrochloride Sustained-Release In The Treatment Of Sexual Dysfunction In Men On Methadone Maintenance Therapy

Phase 2 · Completed · University of Malaya

24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States

Phase 3 · Completed · Sprout Pharmaceuticals, Inc

Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder

Phase 1 · Completed · Sprout Pharmaceuticals, Inc

A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD

Phase 3 · Completed · Sprout Pharmaceuticals, Inc

A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder

Phase 3 · Completed · Sprout Pharmaceuticals, Inc

An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder

Phase 2 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Paraphilic Disorders1
  • Sexual Dysfunctions, Psychological1
Leading journals1
  • Journal of behavioral addictions1
Leading researchers8
  • Ballester-Arnal R1
  • Batthyány D1
  • Bergeron S1
  • Billieux J1
  • Bőthe B1
  • Briken P1
  • Burkauskas J1
  • Cárdenas-López G1
Affiliations (unnormalised)6
  • 11Institute for Behavioural Addictions1
  • 13Institute of Psychology1
  • 14Center for Excessive Gambling1
  • 15Institute for Sex Research1
  • 16Laboratory of Behavioral Medicine1
  • 17Virtual Teaching and Cyberpsychology Laboratory1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty. (APA, DSM-IV, 1994)

Identifiers
MeSHSexual Dysfunctions, Psychological
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.